THERADIAG Announces Its 2022 Financial Calendar
08 Dicembre 2021 - 7:30AM
Business Wire
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker:
ALTER), a company specializing in in vitro diagnostics of
autoimmune diseases and theranostics, today announces its schedule
for the publication of financial information for 2022.
Events
Dates*
2021 Full-Year Annual Revenue
Monday January 31, 2022
2021 Full-Year Results
Monday March 21, 2022
Annual General Meeting
Thursday May 5, 2022
2022 First-Half Sales
Monday June 27, 2022
2022 First-Half Results
Monday September 19, 2022
(*) Subject to modifications. Press releases will be published
before market open.
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2020, the Company posted revenue of €10.4 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
https://www.theradiag.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211207006121/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent Quentin Massé Tel.: +33 (0)1 44 71 94
94 theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Apr 2023 a Apr 2024